PRTA Sep 2023 50.000 put
| Previous close | 2.9400 |
| Open | 2.9400 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 50.00 |
| Expiry date | 2023-09-15 |
| Day's range | 2.9400 - 2.9400 |
| Contract range | N/A |
| Volume | |
| Open interest | 44 |
Business WireProthena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
DUBLIN, May 16, 2023--Prothena announced today the appointment of Dr. Billy Dunn, the founding Director of the Office of Neuroscience, CDER, to its Board of Directors.
ZacksProthena (PRTA) Q1 Earnings and Revenues Miss Estimates
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
ZacksProthena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireProthena Reports First Quarter 2023 Financial Results and Business Highlights
DUBLIN, May 04, 2023--Prothena today reported financial results for the first quarter of 2023 and provided business highlights.
Business WireProthena to Report First Quarter 2023 Financial Results on May 4
DUBLIN, April 27, 2023--Prothena today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023.
ZacksAnalysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireProthena to Participate in 2023 Bank of America Healthcare Conference
DUBLIN, April 24, 2023--Prothena today announced that members of its management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference.
ZacksWalgreens (WBA) Declares Partnership With Prothena Corporation
Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena's Alzheimer's drug candidate, PRX012.
Business WireWalgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial
DEERFIELD, Ill. & DUBLIN, April 13, 2023--Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. As part of the collaboration, Walgreens will leverage its national footprint, portfolio of industry-leading healthca
ZacksProthena (PRTA) Gains 29% in One Year: Will the Momentum Continue?
Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.
Business WireProthena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
DUBLIN, March 31, 2023--Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
Business WireProthena to Participate in Stifel 2023 Virtual CNS Days
DUBLIN, Ireland, March 21, 2023--Prothena announced today that members of its senior management team will participate in a fireside chat at Stifel 2023 Virtual CNS Days on March 28 .
Business WireProthena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
DUBLIN, March 14, 2023--Prothena announced broad participation at AD/PD 2023 highlighting leadership in advancing treatments for Alzheimer’s and Parkinson’s disease
ZacksProthena (PRTA) Q4 Earnings and Revenues Beat Estimates
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
Business WireProthena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
DUBLIN, February 23, 2023--Prothena Corporation plc today reported financial results for the 4th quarter and full year 2022.
Business WireProthena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
DUBLIN, February 16, 2023--Prothena Corporation plc announced that it will report its fourth quarter and full year 2022 financial results on February 23, 2023.
Business WireProthena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, February 03, 2023--Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireProthena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
DUBLIN, January 31, 2023--Prothena announced positive topline Phase 1 SAD study results for PRX005, an investigational tau antibody for the treatment of Alzheimer’s disease.
Business WireProthena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
DUBLIN, December 15, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In add
Business WireProthena Announces Proposed Public Offering of Ordinary Shares
DUBLIN, December 13, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the n
Business WireProthena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
DUBLIN, December 12, 2022--Prothena presented data from phase 3 VITAL study observing a statistically significant survival benefit in patients with Mayo Stage IV AL amyloidosis.
ZacksBiogen (BIIB) Down on Report of Death in Alzheimer's Study
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
ZacksProthena (PRTA) Earns Milestone Payment From Novo Nordisk
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
- Business Wire
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
DUBLIN, November 21, 2022--Prothena announced that it has earned a $40 million milestone payment from Novo Nordisk.
ZacksProthena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.
